Immunovia AB (publ)
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Immunovia AB (publ) (IMMVF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.306x
Based on the latest financial reports, Immunovia AB (publ) (IMMVF) has a cash flow conversion efficiency ratio of -0.306x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.73 Million) by net assets ($64.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunovia AB (publ) - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Immunovia AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Immunovia AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovia AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baikowski SASU
PA:ALBKK
|
0.089x |
|
WVS Financial Corp
OTCQX:WVFC
|
0.019x |
|
Wintergreen Acquisition Corp. Ordinary Shares
NASDAQ:WTG
|
0.000x |
|
FORCS Co.Ltd
KQ:189690
|
0.034x |
|
Autech Corporation
KQ:067170
|
-0.009x |
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
-0.003x |
|
CItech Co Ltd
KO:004920
|
-0.021x |
|
Aura Investments Ltd
TA:AURA
|
-0.169x |
Annual Cash Flow Conversion Efficiency for Immunovia AB (publ) (2013–2025)
The table below shows the annual cash flow conversion efficiency of Immunovia AB (publ) from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.57 Million | $-78.20 Million | -1.211x | +85.42% |
| 2024-12-31 | $11.65 Million | $-96.75 Million | -8.306x | -278.36% |
| 2023-12-31 | $66.99 Million | $-147.06 Million | -2.195x | -204.81% |
| 2022-12-31 | $243.80 Million | $-175.58 Million | -0.720x | -104.71% |
| 2021-12-31 | $433.90 Million | $-152.65 Million | -0.352x | -74.70% |
| 2020-12-31 | $599.40 Million | $-120.70 Million | -0.201x | +21.68% |
| 2019-12-31 | $357.61 Million | $-91.95 Million | -0.257x | -41.22% |
| 2018-12-31 | $461.95 Million | $-84.11 Million | -0.182x | +6.92% |
| 2017-12-31 | $236.80 Million | $-46.32 Million | -0.196x | -355.98% |
| 2016-12-31 | $276.63 Million | $-11.87 Million | -0.043x | +44.96% |
| 2015-12-31 | $83.80 Million | $-6.53 Million | -0.078x | +66.40% |
| 2014-12-31 | $35.74 Million | $-8.29 Million | -0.232x | -176.53% |
| 2013-12-31 | $4.94 Million | $-414.31K | -0.084x | -- |